The Oklahoma Board of Nursing may grant prescriptive authority through the Advanced Practice Registered Nurse license to Certified Nurse Practitioners, Clinical Nurse Specialists, and Certified Nurse-Midwives who meet the requirements for prescriptive authority identified by law and in the Board’s rules. The rules regarding prescriptive authority recognition promulgated by the Oklahoma Board of Nursing pursuant to this section, Section 567.3a of this title, and Sections 1 and 4 of this act shall: 1. Define the procedure for documenting supervision by a supervising physician, as defined in Section 567.3a of this title, of a Certified Nurse Practitioner, Clinical Nurse Specialist, or Certified Nurse-Midwife who has not obtained independent prescriptive authority under Section 1 of this act.
Free access — add to your briefcase to read the full text and ask questions with AI
The Oklahoma Board of Nursing may grant prescriptive authority through the Advanced Practice Registered Nurse license to Certified Nurse Practitioners, Clinical Nurse Specialists, and Certified Nurse-Midwives who meet the requirements for prescriptive authority identified by law and in the Board’s rules. The rules regarding prescriptive authority recognition promulgated by the Oklahoma Board of Nursing pursuant to this section, Section 567.3a of this title, and Sections 1 and 4 of this act shall: 1. Define the procedure for documenting supervision by a supervising physician, as defined in Section 567.3a of this title, of a Certified Nurse Practitioner, Clinical Nurse Specialist, or Certified Nurse-Midwife who has not obtained independent prescriptive authority under Section 1 of this act. Such procedure shall include a written supervision agreement that meets the requirements of Section 4 of this act. The supervision agreement shall be part of the initial application and the renewal application submitted to the Board for recognition for prescriptive authority for the Advanced Practice Registered Nurse. Changes to the supervision agreement shall be filed with the Board within thirty (30) days of the change and shall be effective on filing; 2. Define procedures for assessing the qualifications of applicants for independent prescriptive authority as provided by Section 1 of this act; 3. Define minimal requirements for initial application for prescriptive authority which shall include, but not be limited to, evidence of completion of a minimum of forty-five (45) contact hours or three (3) academic credit hours of education in pharmacotherapeutics, clinical application, and use of pharmacological agents in the prevention of illness, and in the restoration and maintenance of health in a program beyond basic registered nurse preparation, approved by the Board. Such contact hours or academic credits shall be obtained within a time period of three (3) years immediately preceding the date of application for prescriptive authority; 4. Define minimal requirements for application for renewal of prescriptive authority which shall include, but not be limited to, documentation of a minimum of: a. fifteen (15) contact hours or one (1) academic credit hour of education in pharmacotherapeutics, clinical application, and use of pharmacological agents in the prevention of illness, and in the restoration and maintenance of health in a program beyond basic registered nurse preparation, and b. two (2) hours of education in pain management or two (2) hours of education in opioid use or addiction, unless the Advanced Practice Registered Nurse has demonstrated to the satisfaction of the Board that the Advanced Practice Registered Nurse does not currently hold a valid federal Drug Enforcement Administration registration number, approved by the Board, within the two-year period immediately preceding the effective date of application for renewal of prescriptive authority. Such minimal requirements for renewal of prescriptive authority for an Advanced Practice Registered Nurse who has obtained independent prescriptive authority under Section 1 of this act shall include, but not be limited to, documentation that the Advanced Practice Registered Nurse has successfully earned at least forty (40) hours of Category I continuing medical education hours within the two-year period immediately preceding the effective date of application for renewal of independent prescriptive authority, which may include the continuing education described in subparagraphs a and b of this paragraph if such continuing education meets the criteria for Category I continuing medical education; 5. Require that an Advanced Practice Registered Nurse demonstrates successful completion of a master’s degree or higher in one of the following Advanced Practice Registered Nurse roles: a. Certified Nurse Practitioner, b. Clinical Nurse Specialist, or c. Certified Nurse-Midwife, in order to be eligible for initial application for prescriptive authority under the provisions of the Oklahoma Nursing Practice Act; 6. Define the method for communicating authority to prescribe or termination of same, and the formulary to the State Board of Pharmacy, all pharmacies, and all registered pharmacists; 7. Define terminology used in such rules; 8. Define the parameters for the prescribing practices of the Advanced Practice Registered Nurse; 9. Define the methods for termination of prescriptive authority for the Advanced Practice Registered Nurse; and 10. a. Establish a Formulary Advisory Council that shall develop and submit to the Board recommendations for an exclusionary formulary that shall list drugs or categories of drugs that shall not be prescribed by an Advanced Practice Registered Nurse recognized to prescribe by the Oklahoma Board of Nursing. The Formulary Advisory Council shall also develop and submit to the Board recommendations for practice- specific prescriptive standards for each category of Advanced Practice Registered Nurse recognized to prescribe by the Oklahoma Board of Nursing pursuant to the provisions of the Oklahoma Nursing Practice Act. The Board shall either accept or reject the recommendations made by the Council. No amendments to the recommended exclusionary formulary may be made by the Board without the approval of the Formulary Advisory Council. b. The Formulary Advisory Council shall be composed of twelve (12) members as follows: (1) four members, to include a pediatrician, an obstetrician-gynecological physician, a general internist, and a family practice physician; provided, that three of such members shall be appointed by the Oklahoma State Medical Association, and one shall be appointed by the Oklahoma Osteopathic Association, (2) four members who are registered pharmacists, appointed by the Oklahoma Pharmacists Association, and (3) four members, one of whom shall be a Certified Nurse Practitioner, one of whom shall be a Clinical Nurse Specialist, one of whom shall be a Certified Nurse-Midwife, and one of whom shall be a current member of the Oklahoma Board of Nursing, all of whom shall be appointed by the Oklahoma Board of Nursing. c. All professional members of the Formulary Advisory Council shall be in active clinical practice, at least fifty percent (50%) of the time, within their defined area of specialty. The members of the Formulary Advisory Council shall serve at the pleasure of the appointing authority for a term of three (3) years. The terms of the members shall be staggered. Members of the Council may serve beyond the expiration of their term of office until a successor is appointed by the original appointing authority. A vacancy on the Council shall be filled for the balance of the unexpired term by the original appointing authority. d. Members of the Council shall elect a chair and a vice chair from among the membership of the Council. For the transaction of business, at least seven members, with a minimum of two members present from each of the identified categories of physicians, pharmacists, and Advanced Practice Registered Nurses, shall constitute a quorum. The Council shall recommend and the Board shall approve and implement an initial exclusionary formulary on or before January 1, 1997. The Council and the Board shall annually review the approved exclusionary formulary and shall make any necessary revisions utilizing the same procedures used to develop the initial exclusionary formulary.